Shanghai biopharma firm EpimAb raises $25m Series A led by Oriza Seed VC

Shanghai biopharma firm EpimAb raises $25m Series A led by Oriza Seed VC

Juliet Shwe Gaung

26 April, 2017

3E Bioventures Capital Chengbin Wu Decheng Capital Epimab Epimab Biotherapeutics Oriza Holdings Oriza Seed Capital Oriza Seed Venture Capital the Trend Investment Group

Printed by Unregistered user on Wed, 10 Dec 2025 12:53:26 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

Read more from Greater China

Venture Capital

Temasek, HongShan-backed D3 Bio raises $108m in Series B round

Earnings and Results

Chinese sovereign wealth fund CIC’s profit soars 30.4% on investment gains